Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Donepezil Hydrochloride NDC 63629-1118 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Structural Formula - spl image1 structure
Figure 9 - spl image10 figure9
This is a table presenting the mean values and standard errors (SE) for the ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) for two treatments: Donepezil Hydrochloride 10 mg/day and placebo. The table also shows the time of drug treatment which is 3 months and the 2 types of clinical change (improvement and decline).*
Figure 10 - spl image11 figure10
Figure 11 - spl image12 figure11
This is a report on the change from baseline of a drug called Donepezil Hydrochloride. The dosage was changed from 23mg to 10mg per day. The report also mentions a clinical improvement of 57% after weeks of drug treatment.*
Figure 12 - spl image13 figure12
This is a chart showing the cumulative percentage of patients who have taken either 23mg/day or 10mg/day of Donepezil HCI. The chart also shows a change from the baseline. The text includes some errors with non-English characters.*
Figure 13 - spl image14 figure13
Principal Display Panel – 23 mg Bottle Label - spl image15 label
The text describes medication called "Donepezil Hydrochloride" contained in a 90 tablet pack. It is a prescription-only medication that contains 23 mg of USP. The medicine should be kept out of the reach of children and stored in a tight and light-resistant container at a controlled room temperature. The NDC code for this medication pack is 63629-1118-1.*
Figure 1 - spl image2 figure1
Figure 2 - spl image3 figure2
Figure 3 - spl image4 figure3
Figure 4 - spl image5 figure4
This appears to be a graph depicting change in ADAS-cog scores over the course of 15 weeks of drug treatment. The drugs tested were Donepezil Hydrochloride at doses of 10 mg/day and 5 mg/day, compared to placebo. The graph shows an improvement in ADAS-cog scores for the 10 mg/day dose of Donepezil Hydrochloride and a decline in ADAS-cog scores for the placebo group. There is no available data for the 5 mg/day dose.*
Figure 5 - spl image6 figure5
The text represents a chart displaying the changes in ADAS-cop (Alzheimer's Disease Assessment Scale-cognitive subscale) for patients on different treatments. The chart shows the cumulative percentage of patients on placebo, 5mg/day of an unknown treatment, 10mg/day of the same treatment, and 20mg/day of a different treatment. The x-axis shows the change from baseline in the ADAS-cop score, and the y-axis shows the cumulative percentage of patients at each level of change. However, the values for the changes in ADAS-cop are not provided, making it difficult to interpret the chart accurately.*
Figure 6 - spl image7 figure6
This text appears to be a table or a graph showing the effectiveness of different medications, including Donepezil Hydrochloride and Placebo, in improving the condition of patients. The table also indicates the percentage of patients who have experienced marked, moderate, and minimal improvement, or no change or worsening of symptoms. Without any additional information or context, it is difficult to determine the exact purpose or implications of this information.*
Figure 7 - spl image8 figure7
Figure 8 - spl image9 figure8
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.